Published in Br J Clin Pharmacol on September 01, 1986
Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol (1989) 0.88
Propranolol oxidation by human liver microsomes--the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity. Br J Clin Pharmacol (1990) 0.84
Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol (1992) 0.81
Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol (1993) 0.78
Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol. Adv Pharm Bull (2017) 0.75
Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther (1970) 9.54
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol (1981) 3.07
The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology (1972) 2.50
Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther (1973) 2.24
Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci (1971) 2.08
Clinical pharmacokinetics of propranolol. Clin Pharmacokinet (1979) 1.81
Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol (1978) 1.60
The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther (1978) 1.51
Biological determinants of propranolol disposition in man. Clin Pharmacol Ther (1978) 1.35
Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin Pharmacokinet (1983) 1.32
Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry (1984) 1.29
Naphthoxylactic acid after single and long-term doses of propranolol. Clin Pharmacol Ther (1979) 1.10
4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther (1980) 1.00
The inhibitory effect of propranolol pretreatment on its own metabolism in the rat. J Pharmacol Exp Ther (1981) 0.98
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol (1984) 0.94
Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clin Pharmacol Ther (1984) 0.93
Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Br J Clin Pharmacol (1984) 0.93
Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos (1985) 0.92
Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther (1985) 0.88
Presystemic and systemic glucuronidation of propranolol. Clin Pharmacol Ther (1979) 0.86
Simultaneous determination of propranolol and 4-hydroxypropranolol in plasma by mass fragmentography. J Chromatogr (1975) 0.84
Induction of hepatic microsomal propranolol N-desisopropylase activity by 3-methylcholanthrene and Sudan III. Biochem Biophys Res Commun (1982) 0.78
Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol. Clin Pharmacol Ther (1979) 0.78
Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition. J Pharmacol Exp Ther (1982) 0.78
The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther (1978) 1.51
Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther (1986) 1.31
Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol (1999) 1.25
GLC determination of propranolol, other beta-blocking drugs, and metabolites in biological fluids and tissues. J Pharm Sci (1974) 1.22
Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol (2001) 1.21
Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem Pharmacol (1998) 1.18
Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. J Pharmacol Exp Ther (1972) 1.17
Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter SGLT1. J Pharmacol Exp Ther (2000) 1.14
Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Drug Metab Dispos (1996) 1.11
Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol (1998) 1.10
Naphthoxylactic acid after single and long-term doses of propranolol. Clin Pharmacol Ther (1979) 1.10
Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res (2001) 1.06
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther (1989) 1.05
Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos (1998) 1.02
Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther (2000) 1.01
Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin. Clin Pharmacol Ther (1983) 1.01
4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther (1980) 1.00
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation. Pharm Res (2001) 1.00
Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol (1993) 1.00
Methylation protects dietary flavonoids from rapid hepatic metabolism. Xenobiotica (2006) 0.99
Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol (2002) 0.98
The role of the fibrous capsule in the function of implanted drug-polymer sustained release systems. J Biomed Mater Res (1981) 0.98
Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolites. Clin Pharmacol Ther (1981) 0.98
Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica (1999) 0.97
Fate of the flavonoid quercetin in human cell lines: chemical instability and metabolism. J Pharm Pharmacol (1999) 0.95
Acetylation of spermidine and spermine by rat liver and kidney chromatin. Arch Biochem Biophys (1977) 0.95
Stereoselective sulphate conjugation of fenoterol by human phenolsulphotransferases. Xenobiotica (1997) 0.94
Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Br J Clin Pharmacol (1993) 0.93
Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr (2000) 0.93
Taxol metabolism and disposition in cancer patients. Drug Metab Dispos (1995) 0.93
Induction of UDP-glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells. Pharm Res (2000) 0.93
Exercise-induced increments in plasma levels of propranolol and noradrenaline. Br J Clin Pharmacol (1983) 0.92
Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos (1985) 0.92
Reversal of sympathetic nerve blockade: a comparison of dopa, dopamine, and norepinephrine with their alpha-methylated analogues. J Pharmacol Exp Ther (1965) 0.92
Identification of the unusual polyamines 3,3'-diaminodipropylamine and N,N'-bis(3-aminoproply)-1,3-propanediamine in the white shrimp Penaeus setiferus. Biochem Biophys Res Commun (1977) 0.91
Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Mol Biol (2000) 0.90
Human internal mammary artery produces more prostacyclin than saphenous vein. J Thorac Cardiovasc Surg (1986) 0.90
Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women. Br J Clin Pharmacol (1996) 0.90
Stereoselective clearance and distribution of intravenous propranolol. Clin Pharmacol Ther (1984) 0.90
S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytes. J Pharm Pharmacol (2005) 0.89
Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol (1996) 0.89
Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther (1985) 0.88
Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother Pharmacol (1995) 0.88
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab Dispos (2000) 0.88
Hep G2 cell line as a human model for sulphate conjugation of drugs. Xenobiotica (1992) 0.87
Transport of genistein-7-glucoside by human intestinal CACO-2 cells: potential role for MRP2. Res Commun Mol Pathol Pharmacol (1999) 0.87
Carbon dioxide is the major metabolite of quercetin in humans. J Nutr (2001) 0.87
Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique. Res Commun Chem Pathol Pharmacol (1979) 0.87
Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. J Pharmacol Exp Ther (1983) 0.86
Bioactivation of the cooked food mutagen N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells. Carcinogenesis (1998) 0.86
Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans. J Pharmacol Exp Ther (1989) 0.86
Presystemic and systemic glucuronidation of propranolol. Clin Pharmacol Ther (1979) 0.86
Isolation from urine of 4'-hydroxypropranolol sulfate, a major new propranolol metabolite, by ion-pair extraction. J Chromatogr (1984) 0.85
Isopropylamine, a biologically active deamination product of propranolol in dogs: identification of deuterated and unlabeled isopropylamine by gas chromatography-mass spectrometry. J Pharmacol Exp Ther (1972) 0.85
Stimulation-induced release of propranolol and norepinephrine from adrenergic neurons. J Pharmacol Exp Ther (1979) 0.84
Simultaneous determination of propranolol and 4-hydroxypropranolol in plasma by mass fragmentography. J Chromatogr (1975) 0.84
New ring-hydroxylated metabolites of propranolol: species differences and stereospecific 7-hydroxylation. Drug Metab Dispos (1982) 0.84
Propranolol effects on membrane repolarization time in isolated canine Purkinje fibers: threshold tissue content and the influence of exposure time. J Pharmacol Exp Ther (1980) 0.84
Protective effects of trans-13-APT, a thromboxane receptor antagonist, in endotoxemia. J Cardiovasc Pharmacol (1985) 0.84
Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol. Cancer Chemother Pharmacol (1995) 0.83
Identification of major sulfate conjugates in the metabolism of propranolol in dog and man. Drug Metab Dispos (1983) 0.83